Arizona Complete Health-Complete Care Plan (AzCH-CCP) Pharmacy Updates Effective 08/01/22
Date: 07/05/22
Effective August 1, 2022, we’ll implement AHCCCS formulary changes based on the recommendations from the May 24, 2022, AHCCCS Pharmacy & Therapeutics (P & T) Committee. AHCCCS Formulary changes are incorporated into our preferred drug lists located on our website: https://www.azcompletehealth.com/providers/pharmacy.html.
We encourage all prescribing clinicians to review the AzCH-CCP Comprehensive Prescription Drug List (PDL) for preferred formulary alternatives prior to prescribing. The table below highlights some of the upcoming Formulary changes.
Contact our Pharmacy team at 888-788-4408 x 6031278 with any questions.
Thank you!
Drug (s) Removed from Formulary | Preferred Alternative(s) on Formulary (NEW or current alternatives) | Utilization Management (PA, STEP, QL, AGE)** | *Grandfathering permitted (Y/N) | |
Antineoplastic Monoclonal Antibody |
Brand Herceptin (Trastuzumab) | 1. Kanjinti (Transtuzumab-anns) 2. Herzuma (Trastuzumab-pkrb) 3. Trazimera (Trastuzumab-qyyp) 4. Ogivri (Trastuzumab- dkst) 5. 11231 (Trastuzumab-dkst)
| PA | N |
Antineoplastic Monoclonal Antibody | Brand Avastin (Bevacizumab) | 1. Mvasi (Bevacizumab-awwb) 2. Zirabev (Bevacizumab-bvzr)
| PA | N |
Antineoplastic Monoclonal Antibody | Brand Rituxan (Rituximab) | 1. Truxima (Rituximab-abbs) 2. Riabni (Rituximab-arrx) 3. Ruxience (Rituximab-pvvr)
| PA | N |
*AHCCCS P&T determines whether to permit grandfathering (continued use of a non-formulary medication). If grandfathering is not permitted, the member should be transitioned to the preferred formulary alternative and a new prescription may be required. (See AHCCCS Policy 310-V)
** Prior Authorization (PA), Step Therapy (STEP), Quantity Limit (QL), Age Restriction (AGE), Authorized Generic (AG)